Michael A. Parniak
Papers
1
Total Citations
128
H-Index
1
About
Michael A. Parniak is a leading figure in antiretroviral research, whose work has fundamentally shaped our understanding of HIV-1 drug targets and resistance mechanisms. His primary research areas encompass the biochemistry of HIV-1 reverse transcriptase (RT), particularly its associated ribonuclease H (RNase H) activity, and the development of novel inhibitors to combat viral replication. Parniak’s major contributions include pioneering a fluorescence-based high-throughput screening assay for inhibitors of HIV-1 RT RNase H activity, a landmark study published in 2003 that has garnered over 128 citations and remains a cornerstone for drug discovery efforts targeting this essential viral enzyme. Beyond this, his work has elucidated critical structure-function relationships in RT, including the mechanisms of nucleoside and non-nucleoside inhibitor resistance, providing the molecular basis for designing more effective therapies. With a career spanning decades, Parniak’s research has directly influenced the development of clinical candidates and continues to inspire new strategies for overcoming drug resistance. His dedication to translating fundamental virology into practical therapeutic solutions makes him an invaluable resource for students and researchers seeking to understand the complexities of HIV-1 biology and the ongoing fight against the pandemic.
Research Focus
Key Achievements
Top Papers
- 1